Abstract
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
| Original language | English |
|---|---|
| Pages (from-to) | 1396-1398 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 55 |
| Issue number | 7 |
| DOIs | |
| State | Published - Dec 2010 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology
Cite this
Treatment of childhood kaposiform hemangioendothelioma with sirolimus. / Blatt, Julie; Stavas, Joseph; Moats-Staats, Billie; Woosley, John; Morrell, Dean S.
In: Pediatric Blood and Cancer, Vol. 55, No. 7, 12.2010, p. 1396-1398.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of childhood kaposiform hemangioendothelioma with sirolimus
AU - Blatt, Julie
AU - Stavas, Joseph
AU - Moats-Staats, Billie
AU - Woosley, John
AU - Morrell, Dean S.
PY - 2010/12
Y1 - 2010/12
N2 - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
AB - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
UR - http://www.scopus.com/inward/record.url?scp=78049294338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049294338&partnerID=8YFLogxK
U2 - 10.1002/pbc.22766
DO - 10.1002/pbc.22766
M3 - Article
VL - 55
SP - 1396
EP - 1398
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 7
ER -